Top

Published in:

Open Access 01-06-2021 | Atopic Dermatitis | Original Research

Risk of Venous Thromboembolism Among Patients with Atopic Dermatitis: A Cohort Study in a US Administrative Claims Database

Authors: Kristin J. Meyers, Jonathan I. Silverberg, Maria Jose Rueda, Robert Goodloe, Evangeline J. Pierce, Walter Deberdt, Dennis R. Brinker

Published in: Dermatology and Therapy | Issue 3/2021

Abstract

Introduction

Atopic dermatitis (AD) is associated with risk factors for venous thromboembolism (VTE). However, the risk of VTE among this population is unknown. The aim of this study was to assess the risk of VTE among adults with AD and compare the risk vs. matched non-AD controls.

Methods

This retrospective study used claims data from the IBM Watson MarketScan^® Commercial Claims and Encounters, Medicare Supplemental, and Medicaid databases to identify adults aged 18 years or older with AD. Incidence rates (IR) per 100 person-years (PY) of VTE were reported for three cohorts: overall AD, moderate-to-severe AD, and non-AD controls matched by age, sex, and calendar time to the overall cohort. Cox proportional hazards regression was used to estimate hazard ratios (HR) for VTE risk.

Results

Overall, 198,685 patients with AD were identified. Crude VTE IRs were 0.24 for AD overall, 0.31 for moderate-to-severe AD, and 0.25 for non-AD controls. VTE risk was similar in patients with AD vs. non-AD controls (partially adjusted HR 1.00, 95% confidence interval [CI] 0.92, 1.09). VTE risk was greater in patients with moderate-to-severe AD vs. non-AD controls in partially adjusted models (HR 1.24, 95% CI 1.13, 1.36), but not after adjustment for healthcare use and VTE risk factors (HR 0.95, 95% CI 0.85, 1.07).

Conclusions

AD was not an independent risk factor for VTE, and the risk of VTE among patients with AD was low. These findings provide valuable context for understanding VTE risk among patients with AD, which is particularly relevant as advanced therapies for the treatment of moderate to severe AD, such as janus kinase inhibitors, become available.

Available only for authorised users

Silverberg JI. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. 2017;35(3):283–9. https://doi.org/10.1016/j.det.2017.02.002.CrossRefPubMed

Birdi G, Cooke R, Knibb RC. Impact of atopic dermatitis on quality of life in adults: a systematic review and meta-analysis. Int J Dermatol. 2020;59(4):e75–91. https://doi.org/10.1111/ijd.14763.CrossRefPubMed

Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139(3):583–90. https://doi.org/10.1016/j.jid.2018.08.028.CrossRefPubMed

Institute for Health Metrics and Evaluation (IHME). GBD Compare Data Visualization. Seattle, WA: IHME, University of Washington, 2020. http://vizhub.healthdata.org/gbd-compare. Accessed 5 Apr 2021.

Zhang A, Silverberg JI. Association of atopic dermatitis with being overweight and obese: a systematic review and metaanalysis. J Am Acad Dermatol. 2015;72(4):606-16.e4. https://doi.org/10.1016/j.jaad.2014.12.013.CrossRefPubMed

Kantor R, Kim A, Thyssen JP, et al. Association of atopic dermatitis with smoking: a systematic review and meta-analysis. J Am Acad Dermatol. 2016;75(6):1119-25.e1. https://doi.org/10.1016/j.jaad.2016.07.017.CrossRefPubMedPubMedCentral

Silverberg JI, Greenland P. Eczema and cardiovascular risk factors in 2 US adult population studies. J Allergy Clin Immunol. 2015;135(3):721-8.e6. https://doi.org/10.1016/j.jaci.2014.11.023.CrossRefPubMed

Narla S, Hsu DY, Thyssen JP, et al. Inpatient financial burden of atopic dermatitis in the United States. J Invest Dermatol. 2017;137(7):1461–7. https://doi.org/10.1016/j.jid.2017.02.975.CrossRefPubMed

Yu SH, Drucker AM, Lebwohl M, et al. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J Am Acad Dermatol. 2018;78(4):733-40.e11. https://doi.org/10.1016/j.jaad.2017.09.074.CrossRefPubMed

10.

Waljee AK, Rogers MAM, Lin P, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415. https://doi.org/10.1136/bmj.j1415.CrossRefPubMedPubMedCentral

11.

Zhang G, Xu X, Su W, et al. Smoking and risk of venous thromboembolism: a systematic review. Southeast Asian J Trop Med Public Health. 2014;45(3):736–45.PubMed

12.

Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12(8):464–74. https://doi.org/10.1038/nrcardio.2015.83.CrossRefPubMedPubMedCentral

13.

Patel K, Fasanya A, Yadam S, et al. Pathogenesis and epidemiology of venous thromboembolic disease. Crit Care Nurs Q. 2017;40(3):191–200. https://doi.org/10.1097/cnq.0000000000000158.CrossRefPubMed

14.

Ogdie A, Kay McGill N, Shin DB, et al. Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study. Eur Heart J. 2018;39(39):3608–14. https://doi.org/10.1093/eurheartj/ehx145.CrossRefPubMed

15.

Olumiant^® (baricitinib) tablets, for oral use [US prescribing information]. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207924s000lbl.pdf. Accessed 27 Oct 2020.

16.

Xeljanz^® (tofacitinib) tablets, for oral use [US prescribing information]. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203214s018lbl.pdf. Accessed 27 Oct 2020.

17.

Rinvoq^® (upadacitinib) extended-release tablets, for oral use [US prescribing information]. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf. Accessed 27 Oct 2020.

18.

Scott IC, Hider SL, Scott DL. Thromboembolism with janus kinase (JAK) inhibitors for rheumatoid arthritis: how real is the risk? Drug Saf. 2018;41(7):645–53. https://doi.org/10.1007/s40264-018-0651-5.CrossRefPubMed

19.

Fang MC, Fan D, Sung SH, et al. Validity of using inpatient and outpatient administrative codes to identify acute venous thromboembolism: the CVRN VTE study. Med Care. 2017;55(12):e137–43. https://doi.org/10.1097/mlr.0000000000000524.CrossRefPubMedPubMedCentral

20.

Mehta KD, Siddappa Malleshappa SK, Patel S, et al. Trends of inpatient venous thromboembolism in United States before and after the surgeon general’s call to action. Am J Cardiol. 2019;124(6):960–5. https://doi.org/10.1016/j.amjcard.2019.06.015.CrossRefPubMed

21.

Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol. 2007;44(2):62–9. https://doi.org/10.1053/j.seminhematol.2007.02.004.CrossRefPubMedPubMedCentral

22.

Shaheen MS, Silverberg JI. Association of inflammatory skin diseases with venous thromboembolism in US adults. Arch Dermatol Res. 2020. https://doi.org/10.1007/s00403-020-02099-6.CrossRefPubMed

23.

Hsu DY, Dalal P, Sable KA, et al. Validation of International Classification of Disease Ninth Revision codes for atopic dermatitis. Allergy. 2017;72(7):1091–5. https://doi.org/10.1111/all.13113.CrossRefPubMedPubMedCentral

24.

Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–32. https://doi.org/10.1016/j.jaad.2014.03.023.CrossRefPubMedPubMedCentral

25.

Tamariz L, Harkins T, Nair V. A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):154–62. https://doi.org/10.1002/pds.2341.CrossRefPubMed

26.

White RH, Garcia M, Sadeghi B, et al. Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States. Thromb Res. 2010;126(1):61–7. https://doi.org/10.1016/j.thromres.2010.03.009.CrossRefPubMed

27.

Lau BD, Haut ER, Hobson DB, et al. ICD-9 code-based venous thromboembolism performance targets fail to measure up. Am J Med Qual. 2016;31(5):448–53. https://doi.org/10.1177/1062860615583547.CrossRefPubMed

28.

Ohman L, Johansson M, Jansson JH, et al. Positive predictive value and misclassification of diagnosis of pulmonary embolism and deep vein thrombosis in Swedish patient registries. Clin Epidemiol. 2018;10:1215–21. https://doi.org/10.2147/clep.S177058.CrossRefPubMedPubMedCentral

Title: Risk of Venous Thromboembolism Among Patients with Atopic Dermatitis: A Cohort Study in a US Administrative Claims Database
Authors: Kristin J. Meyers
Jonathan I. Silverberg
Maria Jose Rueda
Robert Goodloe
Evangeline J. Pierce
Walter Deberdt
Dennis R. Brinker
Publication date: 01-06-2021
Publisher: Springer Healthcare
Keywords: Atopic Dermatitis
Phlebothrombosis
Published in: Dermatology and Therapy / Issue 3/2021
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI: https://doi.org/10.1007/s13555-021-00538-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2021

Cold Atmospheric Plasma (CAP) for the Treatment of Actinic Keratosis and Skin Field Cancerization: Clinical and High-Frequency Ultrasound Evaluation

Efficacy and Safety of Janus Kinase Inhibitors in Type I Interferon-Mediated Monogenic Autoinflammatory Disorders: A Scoping Review

A New Era for Truncal Acne: Emerging from a Legacy of Neglect

Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature Review

Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results

Pyoderma Gangrenosum with an Underlying Leukocyte Adhesion Deficiency Type 1 (LAD-1) and Pregnancy in the Shade of COVID-19 Epidemic: A Patient and Physician Experience

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials